Navigation Links
Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe

Represents first and only molecular test capable of detecting and measuring all known forms of hepatitis B genotypes, providing a valuable tool for physicians in managing patient therapy.

Abbott and Celera, an Applera Corporation business, announced today that Abbott has received CE marking for a real-time PCR (polymerase chain reaction) test for monitoring hepatitis B (HBV) viral load in patients, allowing the test to be marketed in the European Union. Abbott is marketing the test under its strategic alliance with Celera.

The Abbott RealTime HBV test, developed for use on the Abbott m2000(TM) automated instrument system, is designed for the quantitation (precise measurement) of HBV in human plasma or serum from patients known to be infected with the virus. It is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis and as an aid in assessing a patient's response to antiviral treatment. With the addition of the HBV test, the m2000 offers the broadest menu of molecular tests available on a single instrument platform. The m2000 menu includes real-time PCR tests for HIV-1, hepatitis C, chlamydia, and a combination test for chlamydia and gonorrhea.

Quantitative measurements of HBV levels in plasma or serum have been shown to be an essential parameter in the prognosis and management of patients with HBV. An initial measurement of HBV viral load can guide a decision to begin antiviral therapy, while monitoring HBV DNA levels during therapy can influence its duration and also signal the development of drug resistance.

In addition, the higher the baseline viral level the more likely a patient is to develop hepatocellular carcinoma, a primary cancer of the liver.

"The Abbott RealTime HBV assay is the only test currently available that targets an essential, highly conserved segment of the HBV genome, which makes it a very reliable test for detecting and measuring all known HBV genotypes," said John Robinson, Ph.D., senior director, research and development, Abbott Molecular. "It gives physicians one of the most precise tests available to guide treatment decisions and builds upon Abbott's 30-year legacy in hepatitis testing." HBV genomes have been classified into eight genotypes (A-H). Detecting HBV genotypes is important in terms of both monitoring the disease and guiding treatment decisions. For example, genotype C, which is prevalent in Asia, is considered to be associated with more severe liver disease and development of hepatocellular carcinoma. In contrast, genotype B (also prevalent in the Asia region) has a better prognosis, is rarely associated with hepatocellular carcinoma and seems to have a better response to certain antiviral therapies compared with genotype C.

The Abbott RealTime HBV assay has been developed for use on the Abbott m2000 system, an automated instrument for DNA and RNA testing in molecular laboratories. The m2000 system is based on real-time polymerase chain reaction (PCR) technology and is designed to efficiently detect and measure life-threatening viruses and bacteria in patient serum or plasma samples in less than five hours, compared to other testing methods that may take up to two days. The RealTime HBV test is not intended as a screening test for HBV or as a diagnostic test for confirming the presence of HBV infection.

Abbott currently markets the m2000 system and a menu of tests in countries throughout the world as part of a strategic alliance with Celera.

In Europe, the instrument's menu includes assays for HIV-1 viral load, HCV viral load, chlamydia, and a combination test for chlamydia and gonorrhea.

"We're very pleased that the menu for the m2000 system is expanding in Europe with the registration of the RealTime assay for monitoring hepatitis B viral load," said Kathy Ordonez, president, Celera. "The five tests now approved for sale in Europe on the m2000 system reinforce the system's breadth of menu as a competitive advantage." About Hepatitis B According to the World Health Organization, hepatitis B is a serious global public health problem, but preventable with safe and effective vaccines that have been available since 1982. Of the two billion people who have been infected with the hepatitis B virus, more than 350 million have chronic (lifelong) infections. These chronically infected persons are at high risk of death from cirrhosis of the liver and liver cancer, diseases that kill about one million people each year. Although the vaccine will not cure chronic hepatitis, it is 95 percent effective in preventing chronic infections from developing. The prevalence of HBV infection and the method of transmission vary greatly around the world. In countries with a high prevalence of chronic HBV infection, the most common route of infection is from mother to child at birth or from child to child during early childhood.

In areas of low prevalence, the infection is usually acquired during adulthood through intravenous drug use or high-risk sexual activity.




'"/>




Related medicine news :

1. Abbotts Humira(r) (Adalimumab) Gets Approval by EU for Crohns Disease Treatment
2. Vitamin B for Hepatitis
3. Hepatitis G May Boost HIV Survival
4. Cure for Hepatitis B
5. Hepatitis E virus made impotent
6. Sharing injection equipment spreads Hepatitis C
7. Lymphomas Link to Hepatitis C
8. Hepatitis shots is promising
9. Need for Hepatitis Booster Questioned
10. Good News for HIV Patients Also Suffering From Hepatitis C Virus
11. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) ... and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton ... until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology: